41 min

Trillion Dollar Shot, Episode 2: Bank Breakers The Journal.

    • Daily News

As demand for the new class of GLP-1 weight-loss drugs skyrockets, one thing has stood in the way of many people trying to access them: cost. With a price tag around $1,000 a month for U.S. patients and many insurance companies refusing to cover these drugs for weight loss, patients are often turning to alternatives.

In episode two of “Trillion Dollar Shot,” we look at the roadblocks to making these drugs more affordable, concerns that their high cost will negatively impact U.S. insurance systems, and the sometimes risk-laden options people are turning to in desperation.

Listen: Trillion Dollar Shot, Episode 1: Birth of a Blockbuster  
Learn more about your ad choices. Visit megaphone.fm/adchoices

As demand for the new class of GLP-1 weight-loss drugs skyrockets, one thing has stood in the way of many people trying to access them: cost. With a price tag around $1,000 a month for U.S. patients and many insurance companies refusing to cover these drugs for weight loss, patients are often turning to alternatives.

In episode two of “Trillion Dollar Shot,” we look at the roadblocks to making these drugs more affordable, concerns that their high cost will negatively impact U.S. insurance systems, and the sometimes risk-laden options people are turning to in desperation.

Listen: Trillion Dollar Shot, Episode 1: Birth of a Blockbuster  
Learn more about your ad choices. Visit megaphone.fm/adchoices

41 min

More by The Wall Street Journal

The Journal.
The Wall Street Journal & Gimlet
WSJ What’s News
The Wall Street Journal
WSJ Your Money Briefing
The Wall Street Journal
WSJ Tech News Briefing
The Wall Street Journal
WSJ Minute Briefing
The Wall Street Journal
WSJ’s The Future of Everything
The Wall Street Journal